Knight Therapeutics KHTRF Stock
Knight Therapeutics Price Chart
Knight Therapeutics KHTRF Financial and Trading Overview
| Knight Therapeutics stock price | 6.05 USD |
| Previous Close | 6.01 USD |
| Open | 5.89 USD |
| Bid | 5.89 USD x 30000 |
| Ask | 5.92 USD x 10000 |
| Day's Range | 5.89 - 5.89 USD |
| 52 Week Range | 4.07 - 6.39 USD |
| Volume | 100 USD |
| Avg. Volume | 4.06K USD |
| Market Cap | 578.28M USD |
| Beta (5Y Monthly) | 0.044 |
| PE Ratio (TTM) | 147.25 |
| EPS (TTM) | 0.04 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
KHTRF Valuation Measures
| Enterprise Value | 504.87M USD |
| Trailing P/E | 147.25 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.1328735 |
| Price/Book (mrq) | 1.0142335 |
| Enterprise Value/Revenue | 0.989 |
| Enterprise Value/EBITDA | 7.2 |
Trading Information
Knight Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.044 |
| 52-Week Change | 40.32% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 6.39 USD |
| 52 Week Low | 4.07 USD |
| 50-Day Moving Average | 5.59 USD |
| 200-Day Moving Average | 4.69 USD |
KHTRF Share Statistics
| Avg. Volume (3 month) | 4.06K USD |
| Avg. Daily Volume (10-Days) | 3.67K USD |
| Shares Outstanding | 98.18M |
| Float | 60.24M |
| Short Ratio | N/A |
| % Held by Insiders | 46.95% |
| % Held by Institutions | 20.06% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 1.09% |
| Operating Margin (ttm) | 7.12% |
| Gross Margin | 45.93% |
| EBITDA Margin | 13.73% |
Management Effectiveness
| Return on Assets (ttm) | 0.82% |
| Return on Equity (ttm) | 0.70% |
Income Statement
| Revenue (ttm) | 510.45M USD |
| Revenue Per Share (ttm) | 5.14 USD |
| Quarterly Revenue Growth (yoy) | 68.50% |
| Gross Profit (ttm) | 234.47M USD |
| EBITDA | 70.12M USD |
| Net Income Avi to Common (ttm) | 5.61M USD |
| Diluted EPS (ttm) | 0.04 |
| Quarterly Earnings Growth (yoy) | 502.69% |
Balance Sheet
| Total Cash (mrq) | 143.18M USD |
| Total Cash Per Share (mrq) | 1.46 USD |
| Total Debt (mrq) | 69.78M USD |
| Total Debt/Equity (mrq) | 8.86 USD |
| Current Ratio (mrq) | 2.322 |
| Book Value Per Share (mrq) | 5.8073416 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 105.98M USD |
| Levered Free Cash Flow (ttm) | 66.41M USD |
Profile of Knight Therapeutics
| Country | United States |
| State | QC |
| City | Montreal |
| Address | 100 Boul. Alexis-Nihon |
| ZIP | H4M 2P2 |
| Phone | 514-484-4483 |
| Website | https://www.knighttx.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 830 |
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Q&A For Knight Therapeutics Stock
What is a current KHTRF stock price?
Knight Therapeutics KHTRF stock price today per share is 6.05 USD.
How to purchase Knight Therapeutics stock?
You can buy KHTRF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Knight Therapeutics?
The stock symbol or ticker of Knight Therapeutics is KHTRF.
Which industry does the Knight Therapeutics company belong to?
The Knight Therapeutics industry is Drug Manufacturers - Specialty & Generic.
How many shares does Knight Therapeutics have in circulation?
The max supply of Knight Therapeutics shares is 98.18M.
What is Knight Therapeutics Price to Earnings Ratio (PE Ratio)?
Knight Therapeutics PE Ratio is 151.25002000 now.
What was Knight Therapeutics earnings per share over the trailing 12 months (TTM)?
Knight Therapeutics EPS is 0.04 USD over the trailing 12 months.
Which sector does the Knight Therapeutics company belong to?
The Knight Therapeutics sector is Healthcare.